Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xilio Therapeutics (XLO) Current Leases (2024 - 2025)

Historic Current Leases for Xilio Therapeutics (XLO) over the last 2 years, with Q3 2025 value amounting to $1.3 million.

  • Xilio Therapeutics' Current Leases rose 1310.76% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year increase of 1310.76%. This contributed to the annual value of $1.2 million for FY2024, which is N/A changed from last year.
  • Per Xilio Therapeutics' latest filing, its Current Leases stood at $1.3 million for Q3 2025, which was up 1310.76% from $1.3 million recorded in Q2 2025.
  • Xilio Therapeutics' Current Leases' 5-year high stood at $1.3 million during Q3 2025, with a 5-year trough of $1.1 million in Q1 2024.